Metabolism and Nutrition Research Group, Louvain Drug Research Institute (LDRI), UCLouvain (Université catholique de Louvain), Brussels, Belgium.
WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO Department, WEL Research Institute, Wavre, Belgium.
Diabetologia. 2024 Feb;67(2):333-345. doi: 10.1007/s00125-023-06032-0. Epub 2023 Oct 28.
AIMS/HYPOTHESIS: We aimed to investigate the association between the abundance of Dysosmobacter welbionis, a commensal gut bacterium, and metabolic health in human participants with obesity and diabetes, and the influence of metformin treatment and prebiotic intervention.
Metabolic variables were assessed and faecal samples were collected from 106 participants in a randomised controlled intervention with a prebiotic stratified by metformin treatment (Food4Gut trial). The abundance of D. welbionis was measured by quantitative PCR and correlated with metabolic markers. The in vitro effect of metformin on D. welbionis growth was evaluated and an in vivo study was performed in mice to investigate the effects of metformin and D. welbionis J115 supplementation, either alone or in combination, on metabolic variables.
D. welbionis abundance was unaffected by prebiotic treatment but was significantly higher in metformin-treated participants. Responders to prebiotic treatment had higher baseline D. welbionis levels than non-responders. D. welbionis was negatively correlated with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and fasting blood glucose levels in humans with obesity and type 2 diabetes. In vitro, metformin had no direct effect on D. welbionis growth. In mice, D. welbionis J115 treatment reduced body weight gain and liver weight, and improved glucose tolerance to a better level than metformin, but did not have synergistic effects with metformin.
CONCLUSIONS/INTERPRETATION: D. welbionis abundance is influenced by metformin treatment and associated with prebiotic response, liver health and glucose metabolism in humans with obesity and diabetes. This study suggests that D. welbionis may play a role in metabolic health and warrants further investigation.
NCT03852069.
目的/假设：我们旨在研究共生肠道细菌 Dysosmobacter welbionis 的丰度与肥胖和糖尿病患者代谢健康之间的关系，以及二甲双胍治疗和益生元干预的影响。
对 106 名参与者进行了代谢变量评估，并在一项随机对照干预研究中收集了粪便样本，该研究按二甲双胍治疗（Food4Gut 试验）进行了益生元分层。通过定量 PCR 测量 D. welbionis 的丰度，并将其与代谢标志物相关联。评估了二甲双胍对 D. welbionis 生长的体外影响，并在小鼠中进行了一项体内研究，以研究二甲双胍和 D. welbionis J115 补充剂单独或联合使用对代谢变量的影响。
D. welbionis 的丰度不受益生元治疗的影响，但在接受二甲双胍治疗的参与者中显著更高。对益生元治疗有反应的参与者的基线 D. welbionis 水平高于无反应者。D. welbionis 与肥胖和 2 型糖尿病患者的天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平和空腹血糖水平呈负相关。体外，二甲双胍对 D. welbionis 的生长没有直接影响。在小鼠中，D. welbionis J115 治疗可降低体重增加和肝重，并改善葡萄糖耐量，使其达到比二甲双胍更好的水平，但与二甲双胍没有协同作用。
结论/解释：D. welbionis 的丰度受二甲双胍治疗的影响，并与肥胖和糖尿病患者的益生元反应、肝脏健康和葡萄糖代谢有关。这项研究表明，D. welbionis 可能在代谢健康中发挥作用，值得进一步研究。
NCT03852069。
